TNFRSF1B and rheumatoid arthritis: In particular, they analyzed a total of 105 RA patients (55 treated with etanercept, 40 with infliximab, and 10 with adalimumab), finding that the TNFRII-676TG genotype was significantly associated with lower ACR response compared with -676TT genotype, 3 and 12 months after the beginning of the therapy [126].